Format

Send to

Choose Destination
Drug Resist Updat. 2012 Feb-Apr;15(1-2):98-105. doi: 10.1016/j.drup.2012.03.002. Epub 2012 Apr 6.

Collateral sensitivity as a strategy against cancer multidrug resistance.

Author information

1
Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Abstract

While chemotherapy remains the most effective treatment for disseminated tumors, acquired or intrinsic drug resistance accounts for approximately 90% of treatment failure. Multidrug resistance (MDR), the simultaneous resistance to drugs that differ both structurally and mechanistically, often results from drug efflux pumps in the cell membrane that reduce intracellular drug levels to less than therapeutic concentrations. Expression of the MDR transporter P-glycoprotein (P-gp, MDR1, ABCB1) has been shown to correlate with overall poor chemotherapy response and prognosis. This review will focus on collateral sensitivity (CS), the ability of compounds to kill MDR cells selectively over the parental cells from which they were derived. Insights into CS may offer an alternative strategy for the clinical resolution of MDR, as highly selective and potent CS agents may lead to drugs that are effective at MDR cell killing and tumor resensitization. Four main mechanistic hypotheses for CS will be reviewed, followed by a discussion on quantitative and experimental evaluation of CS.

PMID:
22483810
PMCID:
PMC3348266
DOI:
10.1016/j.drup.2012.03.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center